Fondazione IRCCS Istituto Nazionale Dei Tumori
Fondazione IRCCS Istituto Nazionale Dei Tumori is recorded as a service provider in 10 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 10 of 10 trials · Latest update first
Activity of Pembrolizumab plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma (REPRINT MeetURO trial)
Sponsor Fondazione IRCCS Istituto Nazionale Dei Tumori
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Randomized phase II study of PAnitumumab REchallenge followed by REgorafenib versus the reverse sequence in RAS and BRAF wild-type chemorefractory metastatic colorectal cancer patients. The PARERE trial
Sponsor Fondazione GONO G.I.
- Start (EU)
- Latest update
- Estimated end
- Not reported
EORTC-1809-STBSG: A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
Sponsor European Organisation For Research And Treatment Of Cancer
- Start (EU)
- Latest update
- Estimated end
WINDOW-OF-OPPORTUNITY UMBRELLA PLATFORM TRIAL OF SHORT-COURSE PRE-OPERATIVE OR NEOADJUVANT TARGETED TREATMENT IN PATIENTS WITH MOLECULARLY SELECTED AND RESECTABLE PRIMARY COLORECTAL CANCER: THE UNICORN STUDY
Sponsor Fondazione GONO G.I.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY Study.
Sponsor Fondazione GONO G.I.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patients with persistence of miNImal residual disease in liquid biopsy after pre-operative chemoTherapy and radical surgerY: the TRINITY study
Sponsor Fondazione GONO G.I.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Window-of-opportunity study of chemo-immunotherapy in patients with resectable Merkel Cell Carcinoma prior to surgery: the MERCURY trial
Sponsor Fondazione GONO G.I.
- Start (EU)
- Latest update
- Estimated end
- Not reported
TremelImumab aNd durvalumab combination For the non-operatIve management (NOM) of Microsatellite InstabiliTY (MSI)-high resectable gastric or gastroesophageal junction cancer: The multicentre, single-arm, multi-cohort, Phase II INFINITY study.
Sponsor Fondazione GONO G.I.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours
Sponsor Vall D Hebron Institute Of Oncology
- Start (EU)
- Latest update
- Estimated end
Phase II, multicentre, randomised, open-label trial with MAP +/- denosumab regimen for the treatment of patients with metastatic osteosarcoma
Sponsor Associazione Italiana Ematologia Oncologia Pediatrica
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Fondazione IRCCS Istituto Nazionale Dei Tumori?
The 2026-10-09 snapshot links Fondazione IRCCS Istituto Nazionale Dei Tumori to 10 distinct CTIS trials. Recorded services include Laboratory services, Biological sample storage, Biological sample storage and X-ray images, Clinical monitoring, among 15 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Fondazione IRCCS Istituto Nazionale Dei Tumori?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Urology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Fondazione IRCCS Istituto Nazionale Dei Tumori conducted?
The linked trials record locations in 11 countries, including Italy, Germany, Spain, France, Netherlands. These are trial locations, not confirmed office locations or countries where Fondazione IRCCS Istituto Nazionale Dei Tumori delivered services.
What can this page tell me about Fondazione IRCCS Istituto Nazionale Dei Tumori's trial experience?
Browse 10 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Fondazione IRCCS Istituto Nazionale Dei Tumori. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Fondazione IRCCS Istituto Nazionale Dei Tumori